Bruce Cozadd

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported record third-quarter revenue of $1.05 billion on Wednesday afternoon, up 14% year-over-year, propelled by strong sales of key therapies like Xywav, Epidiolex and Rylaze. The gross margin held steady at 89%. CEO Bruce Cozadd said Jazz remains "...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ), a global biopharmaceutical company and manufacturer of Epidolex, announced its financial results late Tuesday for the full year and fourth quarter of 2021 and provided financial guidance for 2022. "2021 was a transformative year for Jazz,...

Shares of Celator Pharmaceuticals Inc (NASDAQ: CPXX) surged higher by more than 70 percent early Tuesday morning after the company has agreed to be acquired by Jazz Pharmaceuticals plc (NASDAQ: JAZZ) for approximately $1.5 billion, or $30.25 per share. Celator's stock closed for trading at...